Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06057402 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Name: Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) — clinical trial record (NCT06057402)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: MagnetisMM15

StatusRecruiting

PhasePhase 4

SponsorPfizer

Started2023-10-03

View on ClinicalTrials.gov ↗

This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.

Amendment history 3 changes detected by DataLookout

2026-06-17

Trial sites expanded: 28 → 33 locations

2026-05-15

Trial sites expanded: 15 → 28 locations

2026-05-06

Trial sites reduced: 28 → 15 locations

Trial Details

NCT Number	NCT06057402
Lead Sponsor	Pfizer
Conditions	Multiple Myeloma
Enrollment	80 participants
Start Date	2023-10-03
Primary Completion	2032-02-22 (estimated)
Study Completion	2032-02-22 (estimated)
Updated on ClinicalTrials.gov	2026-07-01